Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInventory AverageInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Unicycive Therapeutics (UNCY) Invested Capital (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Invested Capital readings, the most recent being $7.4 million for Q4 2024.

  • On a quarterly basis, Invested Capital rose 295.09% to $7.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $7.4 million, a 295.09% increase, with the full-year FY2024 number at $7.4 million, up 295.09% from a year prior.
  • Invested Capital hit $7.4 million in Q4 2024 for Unicycive Therapeutics, up from -$27.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $10.1 billion in Q2 2023 to a low of -$27.8 million in Q3 2024.
  • Median Invested Capital over the past 4 years was $3.4 million (2023), compared with a mean of $772.5 million.
  • Biggest five-year swings in Invested Capital: skyrocketed 101551.14% in 2023 and later crashed 911.01% in 2024.
  • Unicycive Therapeutics' Invested Capital stood at $16.5 million in 2021, then crashed by 102.83% to -$466000.0 in 2022, then plummeted by 717.38% to -$3.8 million in 2023, then soared by 295.09% to $7.4 million in 2024.
  • The last three reported values for Invested Capital were $7.4 million (Q4 2024), -$27.8 million (Q3 2024), and -$14.8 million (Q2 2024) per Business Quant data.